A 28-year-old woman with schizophrenia has been hospitalized three times in the past 18 months for acute psychotic episodes, each preceded by self-discontinuation of oral risperidone due to forgetting doses and perceived lack of need for medication during periods of stability. During hospitalizations, she responds well to risperidone 4 mg daily within two to three weeks, and tolerates it without significant metabolic or neurological side effects. She has good insight during the current stabilization period and agrees that adherence has been her primary barrier to sustained remission. The PMHNP is planning a transition to a long-acting injectable (LAI) antipsychotic to address the adherence pattern. Which of the following best describes the appropriate LAI treatment planning approach?